ELUXA 3: A phase III study of olmutinib compared to afatinib in patients with non-small-cell lung cancer.

Trial Profile

ELUXA 3: A phase III study of olmutinib compared to afatinib in patients with non-small-cell lung cancer.

Planning
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Olmutinib (Primary) ; Afatinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ELUXA 3
  • Most Recent Events

    • 17 Jun 2016 New trial record
    • 02 Jun 2016 According to Boehringer Ingelheim media release, this trial will be initiated in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top